^
Association details:
| Biomarker: | BRAF wild-type |
|---|---|
| Cancer: | Melanoma |
| Drug: | dacarbazine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA-4 blockadenn(PROMIT: PReconditioning of TumOr, Tumor Microenvironment and the Immune System to ImmunoTherapy)
Excerpt:
......
Trial ID:
Source:
Title:
Successful treatment with dacarbazine against a parathyroid hormone-related protein-producing melanoma causing hypercalcemia after immune checkpoint inhibitor failure
Published date:
04/27/2022
Excerpt:
A 65-year-old Japanese woman had advanced BRAF wild-type melanoma that was refractory to ICI, and then led to hypoxia through exacerbated lung metastases and pleural effusion....Dacarbazine was administered, and after the first administration, the pleural effusion was gradually decreased and hypoxia rapidly disappeared, and the serum calcium and PTHrP levels were improved within normal limits. Dacarbazine after ICI failure is potentially a useful option for oncological emergency due to progression of BRAF wild-type melanoma including PTHrP-producing types.
DOI:
10.1111/1346-8138.16411